home / stock / cstl / cstl news


CSTL News and Press, Castle Biosciences Inc. From 03/25/24

Stock Information

Company Name: Castle Biosciences Inc.
Stock Symbol: CSTL
Market: NYSE
Website: castlebiosciences.com

Menu

CSTL CSTL Quote CSTL Short CSTL News CSTL Articles CSTL Message Board
Get CSTL Alerts

News, Short Squeeze, Breakout and More Instantly...

CSTL - Castle Biosciences Earns a Top Workplaces USA Award for the Third Consecutive Year

Company honored for creating an exceptional, people-first culture that empowers employees and fosters trust, transparency and authenticity Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it has re...

CSTL - Long-term Outcomes Data Shared at SSO 2024 Show That Patients with a Low-Risk DecisionDx®-Melanoma Test Result Were Recurrence Free at Three Years, Including Those Who Utilized the Test to Help Guide the Decision to Avoid an SLNB

Castle’s second presentation at SSO 2024 shows that in a study of 979 patients, DecisionDx-Melanoma demonstrated clinical use value in patients with TI cutaneous melanoma (CM), identifying high-risk patients who could consider a more intensive treatment pathway, such as a sentinel lymph no...

CSTL - When the Price of (CSTL) Talks, People Listen

2024-03-21 16:46:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

CSTL - Leading Squamous Cell Carcinoma Practitioners Publish Consensus Guidelines Integrating DecisionDx®-SCC into a Clinical Workflow to Improve Decision-Making Regarding the Use of Adjuvant Radiation Therapy

The consensus guidelines were drafted by a multidisciplinary panel of radiation oncologists and dermatologists/Mohs micrographic surgeons with expertise in cutaneous squamous cell carcinoma (SCC) management; they provide a recommended framework for using DecisionDx-SCC testing with American Joint...

CSTL - AVLX, SGH and ETNB are among pre market losers

2024-03-15 16:48:33 ET Gainers: 89bio  ( ETNB ) +5% . Black Diamond Therapeutics ( BDTX ) +5% . Anavex Life Sciences  ( AVXL ) +3% . iHeartMedia ( IHRT ) +2% . SMART Global Holdings ( SGH ) +2% . Losers: CERo Th...

CSTL - New Study Shows that the Drug-Drug Interactions and Lifestyle Factors Provided by Castle Biosciences' IDgenetix® Test Significantly Improve Medication Recommendations Over Drug-Gene Interactions Alone for Patients 65 and Older

Study data show that one-third of the IDgenetix-guided medication recommendations were due to drug-drug interactions and lifestyle factors, demonstrating the value of this additional information in guiding selection of neuropsychiatric medications for older adults in cohort of patients 65 and old...

CSTL - Bio-Techne and Qiagen had the biggest increase in short interest levels last month - Baird

2024-03-13 14:01:40 ET More on Qiagen, Bio-Techne, etc. Qiagen N.V. 2023 Q4 - Results - Earnings Call Presentation Qiagen N.V. (QGEN) Q4 2023 Earnings Call Transcript Bio-Techne Corporation (TECH) Q2 2024 Earnings Call Transcript Qiagen upgraded at Morgan Sta...

CSTL - (CSTL) Investment Analysis and Advice

2024-03-11 14:42:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

CSTL - Castle Biosciences to Present New Data Highlighting the Clinical Value of its Dermatologic Tests for Patients with Skin Cancer at the 2024 American Academy of Dermatology (AAD) Annual Meeting

Castle’s presentations at AAD include the latest findings from the Company’s ongoing collaboration with the National Cancer Institute’s Surveillance, Epidemiology, and End Results (SEER) Program Registries, providing new data from a study of more than 5,000 patients confirmin...

CSTL - In Novel Cohort, New Data Confirms DecisionDx®-SCC Provides Significant, Independent and Clinically Actionable Risk-Stratification of Patients, Including in Various High-Risk Subgroups

Largest study of gene expression profile testing in patients with high-risk cutaneous squamous cell carcinoma (SCC) supports test’s ability to provide clinically actionable risk stratification to guide treatment decisions for patients diagnosed with this impactful skin cancer Cas...

Previous 10 Next 10